FINWIRES · TerminalLIVE
FINWIRES

China Overseas Grand Oceans' Contracted Sales Climb 27% in May

By

China Overseas Grand Oceans (HKG:0081) recorded contracted sales and a gross floor area (GFA) of around 3.81 billion yuan and 323,700 square meters in May, up 27% and 25%, respectively, from a year prior, according to a Thursday Hong Kong bourse filing.

For the five months ended May 31, contracted sales and GFA jumped 21% and 20%, respectively, to 15.2 billion yuan and 1.3 million square meters.

As of May 31, property subscription sales stood at 678 million yuan with a GFA of 54,900 square meters.

The property firm did not acquire any land parcels in the month.

Related Articles

Asia

China Overseas Land Logs 27.3 Billion Yuan in May Contracted Sales

China Overseas Land & Investment (HKG:0688) recorded contracted sales of around 27.3 billion yuan in May, up 14% from a year prior, according to a Thursday Hong Kong bourse filing.The property firm's sales area in the month rose 11% to approximately 905,500 square meters.For the five months ended May 31, contracted sales jumped 14% to 103 billion yuan, while sales area fell 6% to over 3.5 million square meters.As of May 31, the firm logged subscribed property sales of about 11.5 billion yuan.New land holdings for the month comprised two land parcels in Zhuhai and Suzhou with an attributable gross floor area of approximately 110,843 square meters and a land premium of 2.49 billion yuan.

$HKG:0688
Asia

Angel One's Client Acquisition Slides 10% in May

Angel One (NSE:ANGELONE, BOM:543235) signed up 420,000 new clients in May, down 9.7% from 500,000 added a year ago, according to the Indian stock exchanges on Thursday.The brokerage services company's client base during the reporting month reached 38.2 million, up 1% from around 32 million a year ago, the filing said.

$BOM:543235$NSE:ANGELONE
Asia

Bao Pharmaceuticals' Application for Desensitization Therapy Drug Accepted in China

Shanghai Bao Pharmaceuticals' (HKG:2659) new drug application for KJ103 for injection was accepted by China's National Medical Products Administration and granted priority review status, according to a Thursday Hong Kong bourse filing.The acceptance is for use of the drug for desensitization therapy in highly sensitized kidney transplant patients.

$HKG:2659